PROSPECTS DOMESTIC DRUGS DIBIKOR (TAURINE) IN PATIENTS WITH MYOCARDIAL INFARCTION, AND STABLE ANGINA
https://doi.org/10.20514/2226-6704-2016-6-3-47-52
Abstract
It was performed the evaluation of the clinical efficacy of taurine in the treatment of postinfarction cardiosclerosis (PIC). 57 patients (mean age 60,2 ± 14,3 years) with evidence of PIC and angina. When incorporated into standard therapy taurine showed a statistically significant improvement (compared to placebo) subjective performance status patients, normalize echocardiographic indices (increase of the ejection fraction) and laboratory parameters (reducing the concentration of total cholesterol, triglycerides, low density lipoprotein). The changes revealed clinical and instrumental parameters are stored for 3 months after receiving taurine. It is recommended to add taurine in a daily dose of 750 mg to standard therapy in patients with postinfarction cardiosclerosis with a view to its potentiating effect by improving the metabolic processes in the myocardium.
About the Authors
V. V. Rezvan
First Moscow State Medical University na I.M. Sechenov
Russian Federation
Russian Federation
Department of Hospital Therapy № 2 Medical Faculty,
Moscow
I. S. Vasilyeva
First Moscow State Medical University na I.M. Sechenov
Russian Federation
Russian Federation
Department of Hospital Therapy № 2 Medical Faculty,
Moscow
N. V. Strizhova
First Moscow State Medical University na I.M. Sechenov
Russian Federation
Russian Federation
Department of Hospital Therapy № 2 Medical Faculty,
Moscow
D. L. Vinogradov
First Moscow State Medical University na I.M. Sechenov
Russian Federation
Russian Federation
Department of Hospital Therapy № 2 Medical Faculty,
Moscow
References
1. VNOC. Diagnosis and treatment of stable angina, 2009. Moscow, 2009; 37 p.
2. Gordeev I.V., Pokrovskaya E.M., Luchinkin E.E. Effect of taurine on the proliferation rate of cardiac arrhythmias, the dispersion of the QT interval in patients with heart failure due to c myocardial infarction: results of a comparative, randomized study. Cardiovascular therapy and prevention. 2012; 11(1): 65-70.
3. Kryuchkov I.V., Adamczyk A.S. Correction of disorders of carbohydrate metabolism and metabolic syndrome. Ros. Cardiology. Zh. 2009; 2: 44-48.
4. Marakhovskii Y.Kh. Amino acids as drugs from scientific advances to clinical practice. III Intern. Scientific-practical Conference. "Experimental and Clinical Pharmacology". Minsk, 2009: 241-242.
5. Shestakova M.V., Chugunova L.A., Shamkhalova M.S. Experience with Dibikor in diabetes mellitus type 2. Diabetes Mellitus. 2007; 1: 30-31.
6. Fedulaev Y.N., Kazantsev A.P., Shchelkunova I.G. et al. Remote method of evaluation results of daily monitoring of ECG in detecting transient myocardial ischemia. Organizational and prognostic aspects. Med. Vestn. Ministry of Internal Affairs. 2007; 3: 25-27.
7. Abebe W., Mozaffari S. Role of taurine in the vasculature: an overview of experimental and human studies. Am. J. Cardiovasc. Dis. 2011; 1(3): 293-311.
8. Brons C.C., Spohr H., Storgaard J., Vaag D. Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. European Journal of Clinical Nutrition. 2004; 58(9): 1239-1247.
9. Bulley S., Shen W. Reciprocal regulation between taurine and glutamate response via Ca2+-de- pendent pathways in retinal third-order neurons. J. Biomed. Scien. 2010; 17(1): 5-10.
10. Casey R.G., Joyce C.G., Hayes D. Taurine attenuates acute hyperglycemia-induced endothelial cell apoptosis, leucocyte-endothelial cell interactions and cardiac dysfunction. J. Vasc. Res. 2007; 44: 31-39.
11. Chapman R.A., Suleiman M.S., Earm Y.E. Taurine and the heart. Cardiovasc. Res. 1993; 27: 358–363.
12. Choi M.J., Kim J.H., Chang K J. The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet. Adv. Exp. Med. Biol. 2006; 583: 235-242.
13. Das J., Vasan V., Sil P. Taurine exerts hypoglycemic effect in alloxaninduced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis. Toxicol. Appl. Pharmacol. 2012; 258: 296–308.
14. Liao X.B., Zhou X.M., Li J.M. et al. Taurine transporter is expressed in vascular smooth muscle cells. Amino Acids. 2007; 33(4): 639–643.
15. Liu Y., Niu L., Zhang W. et al. Effects of taurine on contractions of the porcine coronary artery. Pharmacol. Rep. 2009; 61(4): 681-689.
16. Ochoa-de la Paz L. D., Martinez-Davila I. A., Miledi R. et al. Modulation of human GAB- Arho 1 receptors by taurine. Neurosci. Res. 2008; 61(3): 302-308.
17. Wookey P.J., Zulli A., Buxton B.F., Hare D.L. Calcitonin receptor immunoreactivity associated with specific cell types in diseased radial and internal mammary arteries. Histopathology. 2008; 52: 605–612.
Review
For citations:
Rezvan V.V., Vasilyeva I.S., Strizhova N.V., Vinogradov D.L. PROSPECTS DOMESTIC DRUGS DIBIKOR (TAURINE) IN PATIENTS WITH MYOCARDIAL INFARCTION, AND STABLE ANGINA. The Russian Archives of Internal Medicine. 2016;6(3):47-52. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-3-47-52
Views:
1228
Email this article 